The shares of German chemical company Lanxess (LXS.DE) are trading down 16% today in the face of the earnings warning issued. Moreover, the scale of the sell-off in the company's shares spoils the mood among the larger players listed on the DAX index and the entire chemical company sector on the Old Continent.
Lanxess shares themselves have today slid to their lowest levels in three years. The company decided to lower its operating profit forecasts for the second quarter and full year, reporting that it does not see a recovery in demand in June. Lanxess is not seeing an increase in order volumes for (the third quarter; excluding China), the company revealed. Such a situation puts enormous pressure on the company, as the projected positive impact of improving business dynamics in China may not help the company at all. Moreover, this is a relatively bad prognosis for other companies in the sector, such as BASF (BAS.DE), Evonik (EVK.DE) and Wacker-Chemie (WCH.DE).
The entire European chemical sector is under downward pressure today. Source: xStation5
The company expects EBITDA in the second quarter to be around €100 million ($109 million). Previously, profits were expected to be "about the same" as in the first quarter, which was €189 million.
For the full 2023, EBITDA is expected to be in the range of €600 million to €650 million, compared to the previous forecast of €850 million to €950 million.
Investment bank analysts commenting on the news regarding Lanxess' forecasts mentioned that the dimension of these revisions could significantly affect the entire chemical sector. The company will report its second quarter results on 4 August.
The shares of Lanxess (LXS.DE) open today's session with a sizable bearish price gap and descend to levels not seen in three years. Source: xStation5
From Euphoria to Correction: CoreWeave and the Future of AI Infrastructure
EU Fines for Tech Giants — Their Role in EU/USA Competition
DE40: European stocks are falling as markets await U.S. data
End of Zillow? Google enters another market.
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
